CG Oncology awaits PIVOT-006 Phase 3 data as BLA filing nears
CG Oncology has reported its second-quarter 2026 financial results and set out a series of near-term milestones for cretostimogene grenadenorepvec, its intravesically delivered oncolytic immunotherapy for non-muscle invasive bladder cancer (NMIBC). The Dallas-based company is advancing on two regulatory fronts: topline data from the PIVOT-006 Phase 3 trial in intermediate-risk NMIBC are expected shortly, while the company says it is on track to complete its biologics licence application for high-risk BCG-unresponsive NMIBC by the end of Q4 2026.
Arthur Kuan, chairman and chief executive, said that PIVOT-006 "has accrued the vast majority of the target events" and that the company looks forward to sharing results soon. He described cretostimogene as a prospective "backbone therapy" for bladder cancer patients, though the candidate remains investigational and has not received regulatory approval from the FDA or any other authority.
Clinical and regulatory progress
The BOND-003 Cohort C Phase 3 study, evaluating cretostimogene in high-risk BCG-unresponsive NMIBC patients with carcinoma in situ, was published in The Lancet Oncology in July, providing a peer-reviewed foundation for the forthcoming BLA. Publication in a high-impact journal is a meaningful step: it gives regulators, clinicians and payers a scrutinised dataset to reference, and it strengthens the company's commercial positioning ahead of a potential launch. Earlier in May, CORE-008 Cohort CX data were presented at the American Urological Association Annual Meeting, adding to what is now a clinical programme covering more than 600 patients across multiple NMIBC risk strata.
CG Oncology also secured a legal win in the quarter. The Superior Court of Delaware denied a post-trial motion filed by ANI, upholding a jury verdict in the company's favour relating to a disputed royalty provision. The ruling removes a degree of financial uncertainty heading into a critical regulatory period.
Financial position and market context
The company held approximately $1.0 billion in cash, equivalents and marketable securities at 30 June 2026, down from $1.1 billion at the end of Q1, and said this is sufficient to fund operations through 2029. The quarterly cash burn reflects a significant ramp in expenditure: R&D costs rose to $54.7 million in Q2 2026 from $31.3 million in the same period last year, driven by clinical trial expenses including chemistry, manufacturing and controls costs, and higher headcount. G&A expenses increased to $29.0 million from $17.4 million. The net loss for the quarter was $79.1 million, or $0.90 per share.
The NMIBC treatment landscape has been reshaped in recent years by the withdrawal of several BCG-combination programmes and the FDA's approval of pembrolizumab (Merck) and nadofaragene firadenovec (Ferring) in BCG-unresponsive settings. Cretostimogene, delivered directly into the bladder rather than systemically, is positioned by CG Oncology as a bladder-sparing option that avoids the toxicity profile of systemic checkpoint inhibitors. Whether that differentiation translates into durable commercial advantage will depend heavily on comparative efficacy data and the eventual label the FDA grants. Regulatory feedback on the BLA, expected through the first half of 2027 if submission is completed on schedule, will be the next major inflection point for investors and clinicians alike.
The company's extended cash runway through 2029 provides a meaningful buffer against trial delays or a request for additional data, both of which are not uncommon in the oncology biologics review pathway.